Latest Videos

Aldehyde oxidase (AO) enzyme has gained increasing attention in drug development as one of the alternative approaches to reduce P450-mediated drug metabolism liability. However, clinical failure due to poor prediction of AO-mediated clearance is a major hurdle in development of drugs that are AO substrates.

Scripps Research professor Jeff Kelly shares his research into a broad set of disorders where aberrantly folded proteins lead to degeneration of the heart and/or nervous system.

Chronic inflammation occurs when the immune system spins out of control, and leads to a host of devastating and incurable immune-mediated diseases. Hear how scientists are deciphering new networks of immune regulation that operate locally as opposed to globally and how this can inform the development of safer, more targeted therapies for chronic inflammatory diseases.

A new study led by Scripps Research scientist Howard Hang, PhD, explains how and why a certain species of bacteria in the digestive tract significantly improves the tumor-fighting ability of approved cancer drugs known as checkpoint inhibitors.

Sickle cell disease is one of the most common genetic conditions worldwide, with more than 6 million people living with the disease. This video discusses the potential of CRISPR–Cas9 gene editing as a tool to cure this chronic condition.

Discover what we know (and don’t know) about the causes and treatment of seizures, and what to do if you encounter someone experiencing a seizure.

The MINI 96 is the solution for laboratories that want to fill 96 and 384 well plates faster and more precisely than is possible using traditional handheld pipettes while keeping under budget.

As COVID-19 spread, BioNTech cofounders Uğur Şahin and Özlem Türeci had one goal: to make a safe, effective vaccine faster than ever before.

What is dissolution testing and why is important in drug development, formulation and testing? For this Teach Me in 10 episode, we're joined by Lorraine Kay from Agilent Technologies who gives us a whistle-stop tour of dissolution testing, answering all these questions and more in just 10 minutes.

In this webinar, SEKISUI XenoTech study director Dr. Steven McGreal will cover study design elements and other considerations like timing and characteristics of drugs with high RBC partitioning. He will discuss impacts on PK calculations and provide examples of how RBC partitioning rates can cause errors downstream if not properly investigated early in drug development.